statistiche ricercatore

Continente	#
NA - Nord America	1.598
AS - Asia	500
EU - Europa	451
SA - Sud America	70
AF - Africa	34
Continente sconosciuto - Info sul continente non disponibili	30
OC - Oceania	1
Totale	2.684

Nazione	#
US - Stati Uniti d'America	1.576
SG - Singapore	170
SE - Svezia	144
CN - Cina	118
HK - Hong Kong	83
IT - Italia	72
DE - Germania	70
BR - Brasile	50
VN - Vietnam	42
BG - Bulgaria	41
FR - Francia	34
GB - Regno Unito	32
CA - Canada	17
IN - India	17
AT - Austria	15
TR - Turchia	15
RU - Federazione Russa	14
CI - Costa d'Avorio	12
SN - Senegal	12
JP - Giappone	10
BD - Bangladesh	9
FI - Finlandia	9
SA - Arabia Saudita	8
UA - Ucraina	7
VE - Venezuela	6
AR - Argentina	5
PK - Pakistan	5
BE - Belgio	4
IQ - Iraq	4
AZ - Azerbaigian	3
CL - Cile	3
ID - Indonesia	3
KZ - Kazakistan	3
PH - Filippine	3
PL - Polonia	3
ZA - Sudafrica	3
LB - Libano	2
MA - Marocco	2
MX - Messico	2
NP - Nepal	2
TN - Tunisia	2
AL - Albania	1
AU - Australia	1
BB - Barbados	1
CO - Colombia	1
CR - Costa Rica	1
CZ - Repubblica Ceca	1
EC - Ecuador	1
EG - Egitto	1
HR - Croazia	1
KE - Kenya	1
LA - Repubblica Popolare Democratica del Laos	1
LT - Lituania	1
NG - Nigeria	1
PA - Panama	1
PE - Perù	1
PY - Paraguay	1
RS - Serbia	1
SI - Slovenia	1
SR - Suriname	1
TH - Thailandia	1
UY - Uruguay	1
UZ - Uzbekistan	1
Totale	2.654

Nome	#
Use of low-dose radioiodine ablation for Graves' orbitopathy: results of a pilot, perspective study in a small series of patients	390
Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question	377
Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves’ orbitopathy	266
High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study	246
VARIABLES AFFECTING THE LONG TERM OUTCOME OF GRAVES' ORBITOPATHY FOLLOWING HIGH DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY	192
Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study	191
Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy	174
Choroidal vascularity index in thyroid-associated ophthalmopathy: a cross-sectional study	174
Rehabilitative orbital decompression for Gravesâ orbitopathy: results of a randomized clinical trial	156
Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological study	148
Retinal, choroidal and optic disc analysis in patients with Graves' disease with or without orbitopathy	143
Use of low-dose radioiodine ablation for Gravesâ orbitopathy: results of a pilot, perspective study in a small series of patients	142
null	85
Totale	2.684

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	197	0	3	0	19	50	17	2	6	28	27	4	41
2022/2023	260	34	48	25	18	21	22	2	24	53	0	12	1
2023/2024	115	2	9	10	1	14	25	5	8	2	2	20	17
2024/2025	455	3	12	5	30	56	45	21	14	59	61	54	95
2025/2026	612	59	73	90	49	62	39	84	29	31	67	18	11
2026/2027	601	127	474	0	0	0	0	0	0	0	0	0	0
Totale													2.684

CINECA IRIS Institutional Research Information System